Last edition
News about
Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI™ (enzalutamide) as monotherapy.
Aprotec Offers its Customers Turnkey Systems for Customised Applications
Aprotec has been a specialist in modern, customised solutions in automation, process plant and leak testing technology.
FDA Grants Approval to PPMD DUVYZAT for Duchenne Patients
Parent Project Muscular Dystrophy has been granted approval of DUVYZAT (givinostat) a histone deacetylase (HDAC) inhibitor indicated for individuals diagnosed with Duchenne six years of age and older by FDA.
The acquisition is poised to enhance Lonza's large-scale biologics manufacturing capacity, catering to the growing demand for commercial mammalian contract manufacturing.
NeuExcell Therapeutics Hits New Milestone in Treatment of Malignant Glioma with NXL-004
NeuExcell Therapeutics has successfully given the dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004.
Tonix Pharmaceuticals Secures Dual Manufacturing Partners for Potential Tonmya Launch
The biopharmaceutical company has selected two contract manufacturing organizations (CMOs), with one being Almac Pharma Services, a member of the Almac Group, as dual supply sources for Tonmya™.
Samsung Accepts Healthcare Innovator Award for Contribution to Care in Underserved Communities
Boston Imaging was awarded HHM Health’s Healthcare Innovator Award for its SonoSync technology and contributions to closing the gap in quality, accessible healthcare for underserved communities.
Babson Diagnostics to Launch Transformative Blood Testing Service with Leading Retail Partners
Babson Diagnostics announced that it will launch BetterWay™ blood testing with three retail partners in Austin and San Antonio.
Phanes Therapeutics Earns FDA Fast Track Status for Pancreatic Adenocarcinoma Treatment
Phanes Therapeutics has announced that the US Food and Drug Administration has granted Fast Track designation to PT886 for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma.
Roquette to Acquire IFF Pharma Solutions, Strengthening Position in Pharmaceutical Industry
The merger of Roquette and IFF Pharma Solutions will serve to rebalance Roquette's portfolio around the pillars of Health and Nutrition, expanding its pharma product range and accelerating its growth course.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy